AEON vs. CGTX, KALA, BDRX, AKTX, TELO, COEP, HYPD, OKUR, MAAQ, and KZR
Should you be buying AEON Biopharma stock or one of its competitors? The main competitors of AEON Biopharma include Cognition Therapeutics (CGTX), KALA BIO (KALA), Biodexa Pharmaceuticals (BDRX), Akari Therapeutics (AKTX), Telomir Pharmaceuticals (TELO), Coeptis Therapeutics (COEP), Hyperion DeFi (HYPD), OnKure Therapeutics (OKUR), Mana Capital Acquisition (MAAQ), and Kezar Life Sciences (KZR). These companies are all part of the "pharmaceutical products" industry.
AEON Biopharma vs. Its Competitors
Cognition Therapeutics (NASDAQ:CGTX) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.
43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 14.4% of Cognition Therapeutics shares are held by company insiders. Comparatively, 0.9% of AEON Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Cognition Therapeutics had 7 more articles in the media than AEON Biopharma. MarketBeat recorded 8 mentions for Cognition Therapeutics and 1 mentions for AEON Biopharma. Cognition Therapeutics' average media sentiment score of 0.75 beat AEON Biopharma's score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the media.
Cognition Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.
Cognition Therapeutics presently has a consensus price target of $2.83, suggesting a potential upside of 316.67%. AEON Biopharma has a consensus price target of $360.00, suggesting a potential upside of 46,113.09%. Given AEON Biopharma's higher possible upside, analysts plainly believe AEON Biopharma is more favorable than Cognition Therapeutics.
AEON Biopharma's return on equity of 0.00% beat Cognition Therapeutics' return on equity.
Cognition Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.
Summary
Cognition Therapeutics beats AEON Biopharma on 9 of the 13 factors compared between the two stocks.
Get AEON Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEON and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AEON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AEON Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:AEON) was last updated on 7/18/2025 by MarketBeat.com Staff
Free AEON Stock Alerts